Haleon (NYSE:HLN) Upgraded at BNP Paribas

BNP Paribas upgraded shares of Haleon (NYSE:HLN - Free Report) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports.

A number of other equities analysts have also recently commented on HLN. HSBC reaffirmed a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price objective on the stock in a research note on Friday, May 9th. BNP Paribas Exane raised shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective on the stock in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Finally, Wall Street Zen cut shares of Haleon from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Stock Performance

Shares of Haleon stock traded up $0.03 during trading on Tuesday, reaching $11.36. The company's stock had a trading volume of 24,804,983 shares, compared to its average volume of 8,488,277. The company has a 50-day moving average price of $10.40 and a two-hundred day moving average price of $9.97. The firm has a market cap of $51.17 billion, a PE ratio of 33.41, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon has a fifty-two week low of $8.25 and a fifty-two week high of $11.40. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, analysts forecast that Haleon will post 0.43 EPS for the current year.

Hedge Funds Weigh In On Haleon

A number of institutional investors and hedge funds have recently made changes to their positions in HLN. Wellington Management Group LLP grew its stake in shares of Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock worth $146,232,000 after purchasing an additional 6,175,835 shares during the period. Nuveen LLC acquired a new position in shares of Haleon during the 1st quarter worth $58,870,000. Point72 Asset Management L.P. acquired a new position in shares of Haleon during the 4th quarter worth $45,110,000. Raymond James Financial Inc. acquired a new position in shares of Haleon during the 4th quarter worth $42,193,000. Finally, FMR LLC grew its stake in shares of Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company's stock worth $1,038,217,000 after purchasing an additional 3,909,545 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.